RESEARCH ARTICLE
The Pathophysiology of Antiphospholipid Syndrome
Pablo Ruiz Sada1, Hannah Cohen 2, David Isenberg3, *
Article Information
Identifiers and Pagination:
Year: 2015Volume: 8
Issue: 2
First Page: 2
Last Page: 9
Publisher ID: TOUNJ-8-2
DOI: 10.2174/1874303X01508010002
Article History:
Received Date: 2/7/2014Revision Received Date: 1/9/2014
Acceptance Date: 2/9/2014
Electronic publication date: 20/2/2015
Collection year: 2015

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Abstract
Advances in our knowledge of the pathogenic mechanisms of antiphospholipid syndrome have been achieved in the past few years. Apart from the well-known role of anti-β2-glycoprotein I antibodies, complement, endocrine and genetic factors and a variety of other molecules are now under investigation. These new approaches should lead to novel explanations and potential new treatment options.